Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies
出版年份 2019 全文链接
标题
Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies
作者
关键词
-
出版物
OSTEOPOROSIS INTERNATIONAL
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-05-27
DOI
10.1007/s00198-019-04968-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Fracture Risk After Initiation of Use of Canagliflozin
- (2019) Michael Fralick et al. ANNALS OF INTERNAL MEDICINE
- Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis
- (2019) Hao Wang et al. BMJ Open
- Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study
- (2018) Wen-Hsuan Hou et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Initiation of dapagliflozin and treatment-emergent fractures
- (2018) Konstantinos A. Toulis et al. DIABETES OBESITY & METABOLISM
- The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study
- (2018) John-Michael Gamble et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case–control study
- (2018) E. Losada et al. OSTEOPOROSIS INTERNATIONAL
- Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study
- (2018) Shih-Yi Lin et al. Frontiers in Pharmacology
- Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study
- (2018) Niklas Schmedt et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials
- (2018) Y. S. Zhang et al. OSTEOPOROSIS INTERNATIONAL
- Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials
- (2018) Md Azharuddin et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
- (2017) Yan Zheng et al. Nature Reviews Endocrinology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany—A retrospective analysis of real-world data
- (2017) S. Dombrowski et al. OSTEOPOROSIS INTERNATIONAL
- Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: response to Driessen et al.
- (2017) K. Kostev et al. OSTEOPOROSIS INTERNATIONAL
- Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?
- (2017) J. H. M. Driessen et al. OSTEOPOROSIS INTERNATIONAL
- Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies
- (2017) Mohammad Adil et al. Pharmacological Reports
- Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial
- (2017) Andre Gustavo Daher Vianna et al. Diabetology & Metabolic Syndrome
- The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study
- (2017) Christian Bommer et al. Lancet Diabetes & Endocrinology
- The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials
- (2017) Jun Yang et al. PLoS One
- Insulin use and Excess Fracture Risk in Patients with Type 2 Diabetes: A Propensity-Matched cohort analysis
- (2017) Eladio Losada-Grande et al. Scientific Reports
- The use of incretins and fractures - a meta-analysis on population-based real life data
- (2016) Johanna H. M. Driessen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial
- (2016) Robert G. Josse et al. DIABETES OBESITY & METABOLISM
- Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials
- (2016) H. L. Tang et al. DIABETES OBESITY & METABOLISM
- DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes – A systematic review and meta-analysis
- (2016) Jil Mamza et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES
- (2016) Matthew P. Gilbert et al. Endocrine Practice
- Type 2 Diabetes and Risk of Hip Fractures and Non-Skeletal Fall Injuries in the Elderly: A Study From the Fractures and Fall Injuries in the Elderly Cohort (FRAILCO)
- (2016) Märit Wallander et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study
- (2016) Sumit R. Majumdar et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
- (2016) LANCET
- Mechanisms of diabetes mellitus-induced bone fragility
- (2016) Nicola Napoli et al. Nature Reviews Endocrinology
- Risk of fractures and diabetes medications: a nationwide cohort study
- (2016) H. J. Choi et al. OSTEOPOROSIS INTERNATIONAL
- Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials
- (2016) Jianying Fu et al. Scientific Reports
- Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes
- (2015) Renyuan Li et al. ACTA DIABETOLOGICA
- Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs
- (2015) Johanna H. M. Driessen et al. CALCIFIED TISSUE INTERNATIONAL
- Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis
- (2015) Johanna H. M. Driessen et al. CALCIFIED TISSUE INTERNATIONAL
- Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
- (2015) Ofri Mosenzon et al. DIABETES CARE
- Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
- (2015) B. Bode et al. DIABETES OBESITY & METABOLISM
- Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs
- (2015) Johanna H. M. Driessen et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
- (2014) Zhong-Ning Zhu et al. BONE
- Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
- (2014) Johanna H.M. Driessen et al. BONE
- Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment
- (2014) Lancet Diabetes & Endocrinology
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials (胰高血糖素样肽-1受体激动剂的使用与骨折的关系：一项对随机临床试验的meta分析)
- (2013) Guillaume Mabilleau et al. Journal of Diabetes
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials
- (2011) M. Monami et al. DIABETES CARE
- Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients*
- (2011) Mathijs C. BUNCK et al. Journal of Diabetes
- Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes
- (2010) M. C. Bunck et al. DIABETES OBESITY & METABOLISM
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
- (2008) Y. K. Loke et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Immortal Time Bias in Pharmacoepidemiology
- (2007) S. Suissa AMERICAN JOURNAL OF EPIDEMIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started